These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17620751)

  • 61. The deafening silence of AIDS.
    Cameron E
    Health Hum Rights; 2000; 5(1):7-24. PubMed ID: 11154521
    [No Abstract]   [Full Text] [Related]  

  • 62. International response to the HIV/AIDS epidemic: planning for success.
    Piot P; Coll Seck AM
    Bull World Health Organ; 2001; 79(12):1106-12. PubMed ID: 11799442
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inequalities in HAART uptake and differential survival according to exposure category in Rio de Janeiro, Brazil.
    Lima TA; Beyrer C; Golub JE; Mota JCD; Malta MS; Silva CMFPD; Bastos FI
    Cad Saude Publica; 2018 Aug; 34(8):e00009617. PubMed ID: 30133651
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
    Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
    J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessing and planning home-based care for persons with AIDS.
    McDonnell S; Brennan M; Burnham G; Tarantola D
    Health Policy Plan; 1994 Dec; 9(4):429-37. PubMed ID: 10139475
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Africa, access, and patents: moving fast.
    James JS
    AIDS Treat News; 1999 Jul; (No 322):5-8. PubMed ID: 11366567
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Human resources for treating HIV/AIDS: needs, capacities, and gaps.
    Bärnighausen T; Bloom DE; Humair S
    AIDS Patient Care STDS; 2007 Nov; 21(11):799-812. PubMed ID: 17944556
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The impact of the US president's emergency plan for AIDS relief (PEPFAR) HIV and AIDS program on the Nigerian health system.
    Odekunle FF; Odekunle RO
    Pan Afr Med J; 2016; 25():143. PubMed ID: 28292105
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Taking health promotion on to the streets.
    Filgueiras A
    AIDS Action; 1992 Jun; (17):7. PubMed ID: 12285897
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An appeal for large scale production of antiretroviral drugs in Africa.
    Martial NP; Sieleunou I
    Pan Afr Med J; 2016; 25():18. PubMed ID: 28154710
    [TBL] [Abstract][Full Text] [Related]  

  • 71. How AIDS funding strengthens health systems: progress in pharmaceutical management.
    Embrey M; Hoos D; Quick J
    J Acquir Immune Defic Syndr; 2009 Nov; 52 Suppl 1():S34-7. PubMed ID: 19858936
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries.
    Souteyrand YP; Collard V; Moatti JP; Grubb I; Guerma T
    AIDS; 2008 Jul; 22 Suppl 1():S161-8. PubMed ID: 18664948
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [AIDS: the future of world is in 'their' hands, but comes from 'our' pockets; an impression from the World Aids Conference in South Africa].
    Heij HA
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):389-90. PubMed ID: 11257821
    [No Abstract]   [Full Text] [Related]  

  • 74. Introduction: the realities of antiretroviral therapy rollout: overcoming challenges to successful programmatic implementation.
    Ojikutu B
    J Infect Dis; 2007 Dec; 196 Suppl 3():S445-8. PubMed ID: 18181692
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Conflicts of interest in research involving human beings.
    Greco D; Diniz NM
    J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Community organizations and fighting STDs, HIV and AIDS in Montreal: lessons for sub-Saharan Africa].
    Agonnoude MT; Mesenge C
    Sante; 2010; 20(2):116-24. PubMed ID: 20685643
    [TBL] [Abstract][Full Text] [Related]  

  • 77. One world, one hope: the cost of providing antiretroviral therapy to all nations.
    Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
    AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand.
    Chasombat S; Lertpiriyasuwat C; Thanprasertsuk S; Suebsaeng L; Lo YR
    Southeast Asian J Trop Med Public Health; 2006 Jul; 37(4):704-15. PubMed ID: 17121296
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antiretroviral drug development: the challenge of cost and access.
    Dunne M
    AIDS; 2007 Jul; 21 Suppl 4():S73-9. PubMed ID: 17620756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.